Developer docs
API playgroundTry for free, no card

Search company profiles

Annovis Bio

Full company profile

uuid0000k3r

Namestring
Annovis Bio
Legal namestring
Annovis Bio, Inc.
Websiteurl
annovisbio.com
Company typeenum
Public
Founded yearint
2008
Descriptiontext

Annovis Bio, Inc. (NYSE: ANVS) is a Phase 3 clinical-stage biotechnology company founded in 2008 by Dr. Maria Maccecchini and headquartered in Malvern, Pennsylvania. The company is developing buntanetap (formerly Posiphen/ANVS401), an orally administered small molecule that inhibits translation of multiple neurotoxic aggregating proteins—including APP/amyloid-beta, tau, alpha-synuclein, and TDP-43—through an RNA-targeting mechanism involving Iron Regulatory Protein 1 (IRP1). The in-licensed compound (from the NIH National Institute on Aging in 2009) is being evaluated in two pivotal-stage programs: a 760-patient Phase 3 trial in early Alzheimer's disease across 83 U.S. sites (65% enrolled as of March 2026) and a 500-patient, 36-month open-label Phase 3 extension in Parkinson's disease across 25 U.S. sites launched in January 2026.

The company is pre-revenue and does not yet commercialize any product. Its operating model is funded almost entirely through repeated dilutive public equity offerings, with approximately $112 million raised since IPO in January 2020—including $25 million in October 2025 and $25 million across April–May 2026—to extend the cash runway through approximately Q2 2027. FY2025 financials show R&D expense of $25.2 million, a net loss of $28.9 million ($1.40 per share), and $19.5 million in cash and equivalents. Future revenue, if buntanetap receives FDA approval, would come from commercial drug sales, with pricing and distribution models not yet established.

Annovis serves patients with early-stage Alzheimer's disease (ages 55–85, MMSE 21–28, plasma pTau217 positive) and Parkinson's disease (ages 40–85, H&Y 1–3), with planned indication expansion into Parkinson's disease dementia (FDA Type C meeting January 2026) and broader neurodegeneration. Clinical operations are supported by 83 Alzheimer's and 25 Parkinson's trial sites including academic centers (UCLA, Duke, Rush, UC Davis), and the Parkinson's program integrates NeuroRPM's FDA-cleared AI wearable biomarker platform as a partnered technology layer. The company maintains a small management team (~10–15 members) and a Scientific Advisory Board that includes National Academy members and former directors of the Cleveland Clinic Lou Ruvo Center.

Short descriptiontext

Annovis Bio is a Phase 3 clinical-stage biotechnology company developing buntanetap, an oral small molecule that targets multiple neurotoxic proteins, for patients with early Alzheimer's disease and Parkinson's disease.

Operating statusenum
Operating
Ownership categoryenum
Headcount rangeband
11–50
akta.pro rankint
HeadquartersMalvern, United States
HQ citystring
Malvern
HQ countrystring
United States
HQ regionstring
North America
Markets served

Serves global market

Offices1 record

Each record includes

City, Country, Type, Description, Source

Keyword5 values
neurodegenerative disease therapeutics, Alzheimer's disease treatment, Parkinson's disease treatment, RNA-targeting small molecule, clinical-stage biotechnology
Industry2 codes
PRIMARYHLAIACAC
Neurology & CNS Specialty Pharmaceuticals
SECONDARYHLAIAAAD
Immunology & Inflammation Pharmaceuticals
Healthcare & Life Sciences/Pharmaceuticals/Branded (Innovator) Pharmaceuticals
NAICS code1 code
  • Research and Development in Biotechnology (except Nanobiotechnology)541714
SIC code1 code
  • Medicinal Chemicals & Botanical Products2833
Product category
Neurodegenerative Disease Therapeutics
GTM motion1 record

Each record includes

Type, Description, Source

Revenue model1 record
1Drug Development and Commercialization
TypeOne Time License
Description

Annovis Bio is a pre-revenue clinical-stage biotechnology company. The company raises capital through public offerings of equity to fund clinical development of buntanetap for Alzheimer's and Parkinson's diseases. If buntanetap receives FDA approval, future revenue would come from commercial drug sales.

annovisbio.com
Marketing channels8 records

Each record includes

Title, Type, Stage, Description, Source

Distribution channels3 records

Each record includes

Title, Type, Scope, Target buyer, Description, Source

Cost components5 values
Technology or R&D, Personnel, Operations, Marketing or Sales, Others
GTM typeB2C
B2C
Offering typeHardware or Manufacturing
Hardware or Manufacturing
Core offering1 text field

Annovis Bio is developing buntanetap, an investigational once-daily oral small molecule that targets multiple neurotoxic aggregating proteins (APP, amyloid-beta, tau, alpha-synuclein, TDP-43) through an RNA-targeting translational inhibition mechanism that strengthens binding of mRNAs to Iron Regulatory Protein 1 (IRP1). The drug is in Phase 3 clinical trials for both early Alzheimer's disease and Parkinson's disease, with the company pursuing FDA approval for disease-modifying treatment of neurodegeneration.

Differentiator
Functional benefit
Problem solved
Quantifiable outcome1 of 6 values shown
  • Phase 2/3 Alzheimer's study: 3.3 point improvement in ADAS-Cog11 at 30mg dose vs 0.26 for placebo (p<0.001)
+5 more records
Product overview1 text field

Annovis Bio is a Phase 3 clinical-stage biotechnology company developing buntanetap (formerly Posiphen, ANVS401) as its lead investigational once-daily oral therapy for neurodegenerative diseases, targeting multiple neurotoxic proteins including APP/amyloid-beta, tau, alpha-synuclein, and TDP-43 through a unique RNA-targeting translational inhibition mechanism. The company also has two additional pipeline compounds — ANVS405 and ANVS301 — in earlier stages of development targeting neurodegenerative diseases. In its clinical operations, Annovis Bio has partnered with NeuroRPM to deploy an FDA-cleared AI-powered wearable digital biomarker platform in its ongoing open-label Phase 3 Parkinson's disease study (ANVS-25002), enabling continuous passive monitoring of motor symptoms.

Product and service3 records
1Buntanetap (formerly Posiphen, ANVS401)
CategoryLead drug candidate (Phase 3)
Description

Investigational once-daily oral small molecule that works as a translational inhibitor targeting multiple neurotoxic aggregating proteins (APP, amyloid-beta, tau, alpha-synuclein, TDP-43) through an RNA-targeting mechanism that strengthens binding of mRNAs to Iron Regulatory Protein 1 (IRP1). Designed to halt neurodegeneration in Alzheimer's disease and Parkinson's disease by restoring nerve cell function and communication. Phase 2/3 data showed 3.3 point improvement in ADAS-Cog11 at 30mg dose vs 0.26 for placebo (p<0.001).

2ANVS405
CategoryPipeline drug candidate
Description

Pipeline drug candidate targeting neurodegenerative diseases, listed alongside buntanetap in Annovis Bio's development pipeline. Earlier-stage compound with limited public detail available.

3ANVS301
CategoryPipeline drug candidate
Description

Pipeline drug candidate targeting neurodegenerative diseases, listed alongside buntanetap and ANVS405 in Annovis Bio's development pipeline. Earlier-stage compound with limited public detail available.

Scale indicator13 records

Each record includes

Type, Value, Description, Source

Partnership1 partner
Strategic tierCoreTypeTechnology or IntegrationAnnounced on2026-03-19
Description

Annovis partnered with NeuroRPM to deploy an FDA-cleared AI-powered digital biomarker platform in its ongoing open-label Phase 3 Parkinson's disease study (ANVS-25002). The wearable technology using Apple Watch monitors primary PD symptoms—bradykinesia, tremor, and dyskinesia—in real-world settings, generating digital biomarker data to complement clinical assessments. The partnership aims to provide objective, AI-enabled measurement of disease progression throughout the 36-month trial enrolling 500 patients across 25 U.S. sites.

Recent move7 records

Each record includes

Date, Type, Title, Description, Source

Expansion highlight5 records

Each record includes

Type, Description

Peers10 records
TypeDirect peer
Description

Sage Therapeutics is a CNS-focused biotechnology company that developed Zurzuvae (zuranolone) for postpartum depression. It is comparable to Annovis in CNS specialty pharmaceutical focus, small molecule development, and clinical-to-commercial stage transition experience.

TypeEmerging player
Description

Acadia Pharmaceuticals is a CNS specialty pharma commercializing drugs for Parkinson's disease psychosis (Nuplazid) and Rett syndrome (Daybue). It represents an emerging CNS commercial-stage peer that has navigated the same patient population Annovis targets in PD.

TypeDirect peer
Description

Cognition Therapeutics is a clinical-stage biotech developing CT1812 for Alzheimer's disease and dementia with Lewy bodies. It is a direct peer given similar size, indication focus on neurodegenerative proteinopathies, and small molecule oral therapy modality.

TypeBroad incumbent
Description

Biogen is a large established biotech with deep Alzheimer's franchise including Leqembi (lecanemab) co-developed with Eisai. As the leading AD player, it represents the dominant incumbent competing for the same patient population Annovis targets.

TypeDirect peer
Description

Denali Therapeutics develops therapeutics for neurodegenerative diseases including Parkinson's (LRRK2 inhibitors) and Alzheimer's, with a focus on neurodegeneration biology. It is comparable in indication focus though larger and broader in pipeline.

TypeDirect peer
Description

Athira Pharma was a clinical-stage biotech developing small molecule therapies (fosgonimeton) targeting HGF/MET for Alzheimer's disease and other neurodegenerative disorders. It is a direct peer in indication and clinical-stage status.

TypeDirect peer
Description

Prothena is a clinical-stage biotech developing therapies targeting misfolded proteins (tau, alpha-synuclein, amyloid) in neurodegenerative diseases including Parkinson's and Alzheimer's. It is directly comparable to Annovis in mechanism focus on aggregating neurotoxic proteins.

8Cassava Sciences
TypeDirect peer
Description

Cassava Sciences is a late-stage clinical biotech developing simufilam for Alzheimer's disease. It is the closest direct peer to Annovis Bio in terms of company size, indication focus (early AD), small molecule approach, and pre-revenue clinical-stage status.

9Eisai
TypeBroad incumbent
Description

Eisai co-developed Leqembi (lecanemab) with Biogen and has been a long-standing leader in dementia therapeutics. It is a broad incumbent peer with deep AD commercial and clinical capabilities relevant to buntanetap's target market.

TypeBroad incumbent
Description

Eli Lilly developed Kisunla (donanemab), an FDA-approved anti-amyloid antibody for early Alzheimer's. As a global pharma incumbent with massive AD commercial infrastructure, it is the primary competitive benchmark for any new AD therapeutic.

Market position
Strengths5 records

Each record includes

Headline, Details, Source

Weaknesses5 records

Each record includes

Headline, Details, Source

Competitive moat4 records

Each record includes

Type, Details

Key risks7 records

Each record includes

Headline, Details, Source

Key highlights7 records

Each record includes

Headline, Details, Source

Customer concentration

Classification, Details

Named customers3 records

Each record includes

Name, Industry, Type, Use case, Source, UUID

Segment3 records

Each record includes

Title, Type, Primary, Description, Pain point addressed, Use case, Source

Ideal customer profile3 records

Each record includes

Profile, Firmographic size, Sales motion, Sales cycle length, Buying structure, Purchase trigger, Buyer persona, Geography, Industry vertical, Primary use case, Description, Pain points, Evidence proof points, Target buyer

Technology focused
Yes
API detail
Has APIbool
No

Docs URL, Description

AI capability2 records

Each record includes

Type, Description, Source

AI maturity
App detail

Has app

Feature5 records

Each record includes

Title, Differentiator, Description, Source

Core technology
Revenue estimate
Valuation estimate
Number of profiles
Profiles14 records

Each record includes

Name, Designation, Designation category, Overview, Profile commentary, Source

No data
No data
Funding overview

Funding stage, Last funding date, Total funding USD

Funding rounds18 records

Each record includes

Round, Amount USD, Date, Pre money valuation, Total investors, Investors, News

Investors7 records

Each record includes

Name, Type, Date of entry, Rounds participated, Website

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Each record includes

Name, Acquisition type, Announced date, Completed date, Status, Website, News

Investment

Each record includes

Name, Round, Announced date, Lead investor, Website, News

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Annovis Bio

Neurodegenerative Disease Therapeuticsannovisbio.com

Annovis Bio is a Phase 3 clinical-stage biotechnology company developing buntanetap, an oral small molecule that targets multiple neurotoxic proteins, for patients with early Alzheimer's disease and Parkinson's disease.

What Annovis Bio does

Annovis Bio, Inc. (NYSE: ANVS) is a Phase 3 clinical-stage biotechnology company founded in 2008 by Dr. Maria Maccecchini and headquartered in Malvern, Pennsylvania. The company is developing buntanetap (formerly Posiphen/ANVS401), an orally administered small molecule that inhibits translation of multiple neurotoxic aggregating proteins—including APP/amyloid-beta, tau, alpha-synuclein, and TDP-43—through an RNA-targeting mechanism involving Iron Regulatory Protein 1 (IRP1). The in-licensed compound (from the NIH National Institute on Aging in 2009) is being evaluated in two pivotal-stage programs: a 760-patient Phase 3 trial in early Alzheimer's disease across 83 U.S. sites (65% enrolled as of March 2026) and a 500-patient, 36-month open-label Phase 3 extension in Parkinson's disease across 25 U.S. sites launched in January 2026.

The company is pre-revenue and does not yet commercialize any product. Its operating model is funded almost entirely through repeated dilutive public equity offerings, with approximately $112 million raised since IPO in January 2020—including $25 million in October 2025 and $25 million across April–May 2026—to extend the cash runway through approximately Q2 2027. FY2025 financials show R&D expense of $25.2 million, a net loss of $28.9 million ($1.40 per share), and $19.5 million in cash and equivalents. Future revenue, if buntanetap receives FDA approval, would come from commercial drug sales, with pricing and distribution models not yet established.

Annovis serves patients with early-stage Alzheimer's disease (ages 55–85, MMSE 21–28, plasma pTau217 positive) and Parkinson's disease (ages 40–85, H&Y 1–3), with planned indication expansion into Parkinson's disease dementia (FDA Type C meeting January 2026) and broader neurodegeneration. Clinical operations are supported by 83 Alzheimer's and 25 Parkinson's trial sites including academic centers (UCLA, Duke, Rush, UC Davis), and the Parkinson's program integrates NeuroRPM's FDA-cleared AI wearable biomarker platform as a partnered technology layer. The company maintains a small management team (~10–15 members) and a Scientific Advisory Board that includes National Academy members and former directors of the Cleveland Clinic Lou Ruvo Center.

Annovis Bio firmographics

Firmographics
Name
Annovis Bio
Legal name
Annovis Bio, Inc.
Website
https://annovisbio.com
Company type
Public
Founded year
2008
Operating status
Operating
Headcount range
11–50 employees
Short description
Annovis Bio is a Phase 3 clinical-stage biotechnology company developing buntanetap, an oral small molecule that targets multiple neurotoxic proteins, for patients with early Alzheimer's disease and Parkinson's disease.
Ownership category
akta.pro rank

Annovis Bio industry classification

Industry
Product category
Neurodegenerative Disease Therapeutics
NAICS
Research and Development in Biotechnology (except Nanobiotechnology) (541714)
SIC
Medicinal Chemicals & Botanical Products (2833)
akta.pro industry
PRIMARYHLAIACAC
Neurology & CNS Specialty Pharmaceuticals
SECONDARYHLAIAAAD
Immunology & Inflammation Pharmaceuticals
Healthcare & Life Sciences/Pharmaceuticals/Branded (Innovator) Pharmaceuticals

Keywords

  • Neurodegenerative disease therapeutics
  • Alzheimer's disease treatment
  • Parkinson's disease treatment
  • RNA-targeting small molecule
  • Clinical-stage biotechnology

Where Annovis Bio is headquartered

Location

Headquarters

HQ city
Malvern
HQ country
United States
HQ region
North America

Offices1 record

Markets served

Annovis Bio business model

Business model
GTM type
B2C
Offering type
Hardware or Manufacturing
Cost components
Technology or R&D, Personnel, Operations, Marketing or Sales, Others

Revenue model

  1. Drug Development and Commercialization: Annovis Bio is a pre-revenue clinical-stage biotechnology company. The company raises capital through public offerings of equity to fund clinical development of buntanetap for Alzheimer's and Parkinson's diseases. If buntanetap receives FDA approval, future revenue would come from commercial drug sales.

Go-to-market motion1 record

Distribution channels3 records

Marketing channels8 records

Annovis Bio product offering

Product offering

Core offering

Annovis Bio is developing buntanetap, an investigational once-daily oral small molecule that targets multiple neurotoxic aggregating proteins (APP, amyloid-beta, tau, alpha-synuclein, TDP-43) through an RNA-targeting translational inhibition mechanism that strengthens binding of mRNAs to Iron Regulatory Protein 1 (IRP1). The drug is in Phase 3 clinical trials for both early Alzheimer's disease and Parkinson's disease, with the company pursuing FDA approval for disease-modifying treatment of neurodegeneration.

Product overview

Annovis Bio is a Phase 3 clinical-stage biotechnology company developing buntanetap (formerly Posiphen, ANVS401) as its lead investigational once-daily oral therapy for neurodegenerative diseases, targeting multiple neurotoxic proteins including APP/amyloid-beta, tau, alpha-synuclein, and TDP-43 through a unique RNA-targeting translational inhibition mechanism. The company also has two additional pipeline compounds — ANVS405 and ANVS301 — in earlier stages of development targeting neurodegenerative diseases. In its clinical operations, Annovis Bio has partnered with NeuroRPM to deploy an FDA-cleared AI-powered wearable digital biomarker platform in its ongoing open-label Phase 3 Parkinson's disease study (ANVS-25002), enabling continuous passive monitoring of motor symptoms.

Differentiator

Problem solved

Functional benefit

Products and services

  • Buntanetap (formerly Posiphen, ANVS401) Investigational once-daily oral small molecule that works as a translational inhibitor targeting multiple neurotoxic aggregating proteins (APP, amyloid-beta, tau, alpha-synuclein, TDP-43) through an RNA-targeting mechanism that strengthens binding of mRNAs to Iron Regulatory Protein 1 (IRP1). Designed to halt neurodegeneration in Alzheimer's disease and Parkinson's disease by restoring nerve cell function and communication. Phase 2/3 data showed 3.3 point improvement in ADAS-Cog11 at 30mg dose vs 0.26 for placebo (p<0.001).
  • ANVS405 Pipeline drug candidate targeting neurodegenerative diseases, listed alongside buntanetap in Annovis Bio's development pipeline. Earlier-stage compound with limited public detail available.
  • ANVS301 Pipeline drug candidate targeting neurodegenerative diseases, listed alongside buntanetap and ANVS405 in Annovis Bio's development pipeline. Earlier-stage compound with limited public detail available.

Quantifiable outcome

  • Phase 2/3 Alzheimer's study: 3.3 point improvement in ADAS-Cog11 at 30mg dose vs 0.26 for placebo (p<0.001)
  • +5 more outcomes

Companies that use Annovis Bio

Customer profile

Named customers3 records

Segments3 records

Ideal customer profiles3 records

Annovis Bio technology and API

Technology

Technology focussed Yes

API detail

Has API
No
API docs
API detail

Core technology

AI maturity

App detail

AI capability2 records

Feature5 records

Annovis Bio partnerships and signals

Strategic signal

Partnerships

One partnership is on record.

  • NeuroRPMcoreTechnology or Integration · 19 March 2026Annovis partnered with NeuroRPM to deploy an FDA-cleared AI-powered digital biomarker platform in its ongoing open-label Phase 3 Parkinson's disease study (ANVS-25002). The wearable technology using Apple Watch monitors primary PD symptoms—bradykinesia, tremor, and dyskinesia—in real-world settings, generating digital biomarker data to complement clinical assessments. The partnership aims to provide objective, AI-enabled measurement of disease progression throughout the 36-month trial enrolling 500 patients across 25 U.S. sites.

Scale indicators13 records

Recent moves7 records

Expansion highlights5 records

Annovis Bio competitors and assessment

Company assessment

Direct peers

  • Sage Therapeutics: Sage Therapeutics is a CNS-focused biotechnology company that developed Zurzuvae (zuranolone) for postpartum depression. It is comparable to Annovis in CNS specialty pharmaceutical focus, small molecule development, and clinical-to-commercial stage transition experience.
  • Cognition Therapeutics: Cognition Therapeutics is a clinical-stage biotech developing CT1812 for Alzheimer's disease and dementia with Lewy bodies. It is a direct peer given similar size, indication focus on neurodegenerative proteinopathies, and small molecule oral therapy modality.
  • Denali Therapeutics: Denali Therapeutics develops therapeutics for neurodegenerative diseases including Parkinson's (LRRK2 inhibitors) and Alzheimer's, with a focus on neurodegeneration biology. It is comparable in indication focus though larger and broader in pipeline.
  • Athira Pharma: Athira Pharma was a clinical-stage biotech developing small molecule therapies (fosgonimeton) targeting HGF/MET for Alzheimer's disease and other neurodegenerative disorders. It is a direct peer in indication and clinical-stage status.
  • Prothena Corporation: Prothena is a clinical-stage biotech developing therapies targeting misfolded proteins (tau, alpha-synuclein, amyloid) in neurodegenerative diseases including Parkinson's and Alzheimer's. It is directly comparable to Annovis in mechanism focus on aggregating neurotoxic proteins.
  • Cassava Sciences: Cassava Sciences is a late-stage clinical biotech developing simufilam for Alzheimer's disease. It is the closest direct peer to Annovis Bio in terms of company size, indication focus (early AD), small molecule approach, and pre-revenue clinical-stage status.

Emerging players

  • Acadia Pharmaceuticals: Acadia Pharmaceuticals is a CNS specialty pharma commercializing drugs for Parkinson's disease psychosis (Nuplazid) and Rett syndrome (Daybue). It represents an emerging CNS commercial-stage peer that has navigated the same patient population Annovis targets in PD.

Broad incumbents

  • Biogen: Biogen is a large established biotech with deep Alzheimer's franchise including Leqembi (lecanemab) co-developed with Eisai. As the leading AD player, it represents the dominant incumbent competing for the same patient population Annovis targets.
  • Eisai: Eisai co-developed Leqembi (lecanemab) with Biogen and has been a long-standing leader in dementia therapeutics. It is a broad incumbent peer with deep AD commercial and clinical capabilities relevant to buntanetap's target market.
  • Eli Lilly: Eli Lilly developed Kisunla (donanemab), an FDA-approved anti-amyloid antibody for early Alzheimer's. As a global pharma incumbent with massive AD commercial infrastructure, it is the primary competitive benchmark for any new AD therapeutic.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat4 records

Key risks7 records

Key highlights7 records

Customer concentration

Annovis Bio social profiles

Digital presence

Annovis Bio financial estimates

Financial estimate

Revenue estimate

Valuation estimate

Annovis Bio leadership team

Management profile

Number of profiles

Profiles14 records

Annovis Bio funding detail

Funding detail

Funding overview

Funding rounds18 records

Investors7 records

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

Annovis Bio M&A and investment

M&A and investment

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Annovis Bio

What does Annovis Bio do?

Annovis Bio is developing buntanetap, an investigational once-daily oral small molecule that targets multiple neurotoxic aggregating proteins (APP, amyloid-beta, tau, alpha-synuclein, TDP-43) through an RNA-targeting translational inhibition mechanism that strengthens binding of mRNAs to Iron Regulatory Protein 1 (IRP1). The drug is in Phase 3 clinical trials for both early Alzheimer's disease and Parkinson's disease, with the company pursuing FDA approval for disease-modifying treatment of neurodegeneration.

Is Annovis Bio a public or private company?

Annovis Bio is a public company. It is classified as public and is currently operating.

When was Annovis Bio founded?

Annovis Bio was founded in 2008. It employs 11 to 50 people.

Where is Annovis Bio based?

Annovis Bio is headquartered in Malvern, United States, in the North America region.

How does Annovis Bio make money?

One revenue line is on record: drug Development and Commercialization.

Who are Annovis Bio's main competitors?

Direct peers on record are Sage Therapeutics, Cognition Therapeutics, Denali Therapeutics, Athira Pharma, Prothena Corporation and Cassava Sciences. Acadia Pharmaceuticals is listed as an emerging player. Broad incumbents are Biogen, Eisai and Eli Lilly.

Does Annovis Bio have an API?

No public API is recorded for Annovis Bio.

What industry is Annovis Bio in?

Annovis Bio's product category is Neurodegenerative Disease Therapeutics. Its primary akta.pro industry code is HLAIACAC, Neurology & CNS Specialty Pharmaceuticals, with a secondary code of HLAIAAAD, Immunology & Inflammation Pharmaceuticals. Its NAICS code is 541714 and its SIC code is 2833.

Unlock the full company data

50 free credits on sign-up, no credit card required.

Contact sales
Live signals
TradingViewAnnovis Bio, Inc. (ANVS) Gets FDA Agreement on Buntanetap Safety Data Pooling PlanThe FDA agreed to Annovis Bio's plan to pool buntanetap safety data from four Alzheimer's and Parkinson's studies for a planned NDA. The pooled analysis covers three randomized, placebo-controlled studies and one open-label extension, with over 1,600 participants expected by the DUET-AD readout. NDA submission is intended after that readout.GlobeNewswirePRISM MarketView Highlights Four Small Caps Working on Alzheimer’s Disease for National Alzheimer’s Disease Awareness MonthPRISM MarketView published a feature on four small-cap companies developing Alzheimer's treatments and tests, following the CTAD conference. Biogen's diranersen slowed decline by 38% at two years, while Priavoid's PRI-002 missed its endpoint and Lilly is ending mevidalen development. Annovis Bio expects Phase 3 results in March 2027, and IGC Pharma's CALMA trial topline is due in December 2026 or January 2027.Longevity.TechnologyAnnovis’ Phase 3 Alzheimer’s trial gets second safety clearanceAnnovis announced a second consecutive positive safety recommendation for its Phase 3 trial of buntanetap in early Alzheimer's disease. The independent Data and Safety Monitoring Board reviewed safety data through September 22, 2026, covering 861 patients at different dosing stages.TradingViewAnnovis Bio, Inc. (ANVS) Gets Second Positive DSMB Review for Phase 3 TrialAnnovis Bio's DSMB recommended continuing its Phase 3 DUET-AD trial without modification after reviewing safety data from 861 patients through September 22, 2026. Six-month topline results are expected in March 2027, with database lock planned for February 8, 2027.The future of tradingAnnovis Bio Presents Buntanetap Development Update, Targets Alzheimer’s Drug Application in 2027Annovis Bio expects symptomatic data from its Phase 3 DUET-AD Alzheimer's trial in Q1 2027, with a symptomatic-treatment NDA target in Q1 2027 and a disease-modifying NDA in Q1 2028. The trial is fully enrolled with 862 participants, and the completed Parkinson's trial met endpoints. Cash totaled $21 million with no debt.FinancialContent Business PageBioMedNewsBreaks – Annovis Bio Inc. (NYSE: ANVS) Reports Q3 Updates, Targets March 2027 Phase 3 Alzheimer Data ReadoutAnnovis Bio reported Q3 2026 updates, including full enrollment of 862 patients in its Phase 3 DUET-AD trial and 326 patients in a Parkinson's extension. The company closed a $21 million underwritten public offering and expects topline results from the six-month treatment period in March 2027.The future of tradingAnnovis Bio Inc reports results for the quarter ended September 30 - Earnings SummaryAnnovis Bio Inc reported a quarterly adjusted loss of 22 cents per share for the quarter ended September 30, higher than the prior year's -37 cents. Revenue was zero, and shares fell 33.3% this quarter and 75.5% year-to-date. Analysts' mean estimate was -37 cents, and the average rating is buy with a $9.00 price target.Longevity.TechnologyAnnovis secures patent for new Alzheimer’s drug formulationAnnovis received U.S. Patent No. 12,780,831 for a new crystalline form of posiphen (Buntanetap), designated Form B, which the company says is a highly crystalline dihydrate distinct from the previously used semi-crystalline anhydrate Form A.Business & FinancialBiomednewsbreaks Annovis Bio Inc. (NYSE: ANVS) Reports Q3 Updates, Targets March 2027 Phase 3 Alzheimer Data ReadoutAnnovis Bio reported Q3 updates, including enrollment of 326 patients in its Parkinson's disease open-label extension study. The company closed a $21 million underwritten public offering on Nov. 6, 2026, with a $5 million board chairman investment. Management expects the financing to support operations through the anticipated March 2027 topline data readout.TradingViewAnnovis Bio Director Purchased Shares Worth Over $5MAnnovis Bio director Michael B. Hoffman purchased 5,000,000 shares at $1.00 per share, totaling $5,000,000. After the transaction, he directly owned 8,364,883 shares and indirectly owned 223,357 shares through his family trust.